ABVC BioPharma, Inc. Equity Method Investments
ABVC BioPharma, Inc. (ABVC) had Equity Method Investments of -$31.42 thousand as of 2026-03-31, per its 10-Q filed 2026-05-18.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments
us-gaap:EquityMethodInvestments · last filed 2026-05-18
- 2026-03-31: Equity Method Investments -$31.42K.
- 2025-12-31: Equity Method Investments -$192.76K.
- 2025-06-30: Equity Method Investments -$95.79K.
- 2025-03-31: Equity Method Investments -$50.88K.
| Period end | Equity Method Investments | Equity Method Investments as first filed |
|---|---|---|
| 2026-03-31 | -$31.42K 10-Q · filed 2026-05-18 | |
| 2025-12-31 | -$192.76K 10-K · filed 2026-03-03 | |
| 2025-06-30 | -$95.79K 10-Q · filed 2025-08-13 | |
| 2025-03-31 | -$50.88K 10-Q · filed 2026-05-18 | |
| 2024-12-31 | -$339.17K 10-K · filed 2026-03-03 | |
| 2024-09-30 | $146.94K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$79.06K 10-Q · filed 2025-08-13 | |
| 2024-03-31 | -$79.06K 10-Q · filed 2025-08-13 | $2.47M 10-Q · filed 2024-05-17 |
| 2023-12-31 | -$221.89K 10-K · filed 2025-04-15 | $2.53M 10-K · filed 2024-03-13 |
| 2023-09-30 | $2.68M 10-Q · filed 2023-11-15 | |
| 2023-06-30 | $831.71K 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $849.84K 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $842.07K 10-K · filed 2024-03-13 | |
| 2022-09-30 | $816.16K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $870.57K 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $904.25K 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $932.75K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $1.01M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $1.10M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $1.13M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $1.19M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $1.19M 10-Q · filed 2020-11-17 | |
| 2020-06-30 | $2.20M 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $3.26M 10-Q · filed 2020-06-29 | |
| 2019-12-31 | $3.36M 10-K · filed 2021-03-16 | |
| 2019-09-30 | $3.27M 10-Q · filed 2019-11-18 | |
| 2019-06-30 | $3.34M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $3.41M 10-Q · filed 2019-05-28 | |
| 2018-12-31 | $3.49M 10-K · filed 2020-05-15 |